(lp0
S'Insider Trading Activity Clovis Oncology Inc   Insider Sold 3000 ... Market Exclusive - 9 hours ago On 8/16/2012 Edward J Mckinley, Director, bought 9,701 with an average share price of $15.50 per share and the total transaction amounting to $150,365.50.'
p1
aS'Analyst Activity  Goldman Sachs Group Inc Raises Its Price Target On Clovis ... Market Exclusive - 7 hours ago Today, Goldman Sachs Group Inc raised its price target on Clovis Oncology  to per share. There are 1 sell rating, 4 hold ratings, 7 buy ratings on the stock.Apple, Netflix, Clovis Oncology Upgraded - Schaeffers Research Just the Facts on Clovis Oncology, Inc.  - StockNewsJournal'
p2
aS'Clovis Oncology Inc.  Breaks into New 52-Week High on March 15 Session Equities.com - 11 hours ago Shares of Clovis Oncology Inc.  broke into a new 52-week high yesterday, hitting a peak of $73.81. Shares closed at $71.93 after opening at $66.95 for a move of 7.44%.'
p3
aS'Clovis Oncology Presents New Data from Phase 2 Studies of Rucaparib in ... Business Wire  - Mar 12, 2017 BOULDER, Colo.----Clovis Oncology, Inc.  announced new data from parts 1 and 2 of the ongoing ARIEL2 Phase 2 study being presented today at the 2017 Society of Gynecologic Oncology  Annual Meeting on&nbsp;...'
p4
aS"Average Brokerage Rating Of Nivalis Therapeutics, Inc. , Clovis Oncology ... The USA Commerce - 17 hours ago Shares of Nivalis Therapeutics, Inc.  surged 1.37% to $2.96. During the trading on 03/14/2017, Company's stock ranged from $2.92 to $3.63."
p5
aS'Update in Lawsuit for Investors in shares of Clovis Oncology Inc (NASDAQ:CLVS ... Yahoo Finance - Feb 14, 2017 14, 2017  -- The Shareholders Foundation, Inc. announces that a lawsuit is pending in Colorado on behalf of certain purchasers of shares of Clovis Oncology Inc  over alleged Securities Laws Violations by Clovis Oncology.Clovis Oncology, Inc.  Long-Term Growth Estimate At $29.42 - Transcript Daily'
p6
aS"Clovis Oncology Announces 2016 Operating Results Yahoo Finance - Feb 22, 2017 Clovis Oncology, Inc.  reported financial results for the quarter and year ended December 31, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for 2017.JP Morgan Boosts Price Target for Clovis Oncology Inc  on Back of ... - Smarter AnalystCommit To Purchase Clovis Oncology At $35, Earn 12.3% Using Options - Nasdaq"
p7
aS'Johnson &amp; Weaver, LLP Announces Investigations of Clovis Oncology, Inc., USANA ... PR Newswire  - Feb 19, 2017 SAN DIEGO, Feb. 18, 2017 /PRNewswire/ -- Shareholder Rights Law Firm Johnson &amp; Weaver, LLP is investigating potential claims against Clovis Oncology, Inc., USANA Health Sciences, Inc., Anthera Pharmaceuticals, Inc., and PixarBio Corporation,&nbsp;...'
p8
aS'Clovis Oncology Inc Risk Points versus Health Care CML News - Mar 8, 2017 This is a scatter plot analysis of the critical risk points from the option market for Clovis Oncology Inc  compared to its own past and the Health Care ETF.Clovis Oncology, Inc. , PDC Energy, Inc.  Stock Eyes Ahead of Earnings - The USA Commerce'
p9
aS"What are Analyst's Indicators for Clovis Oncology, Inc. , Matador ... The USA Commerce - Mar 13, 2017 Shares of Clovis Oncology, Inc.  surged 3.45% to $62.40. During the trading on 03/10/2017, Company's stock ranged from $60.07 to $62.49.Pay Too Much Attention To Two Stock Analyst Ratings: Clovis Oncology, Inc ... - The Voice Registrar"
p10
a.